531 related articles for article (PubMed ID: 32971948)
21. Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival.
Oshi M; Tokumaru Y; Angarita FA; Lee L; Yan L; Matsuyama R; Endo I; Takabe K
Sci Rep; 2021 Jun; 11(1):12541. PubMed ID: 34131208
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of tumor-infiltrating lymphocyte subtypes in residual tumors of patients with triple-negative breast cancer after neoadjuvant chemotherapy.
Bai YG; Gao GX; Zhang H; Zhang S; Liu YH; Duan XN; Xu L
Chin Med J (Engl); 2020 Mar; 133(5):552-560. PubMed ID: 32044815
[TBL] [Abstract][Full Text] [Related]
23. Tumor-infiltrating lymphocytes and CD8
Vihervuori H; Autere TA; Repo H; Kurki S; Kallio L; Lintunen MM; Talvinen K; Kronqvist P
J Cancer Res Clin Oncol; 2019 Dec; 145(12):3105-3114. PubMed ID: 31562550
[TBL] [Abstract][Full Text] [Related]
24. Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor-positive breast cancer.
Egelston CA; Guo W; Tan J; Avalos C; Simons DL; Lim MH; Huang YJ; Nelson MS; Chowdhury A; Schmolze DB; Yim JH; Kruper L; Melstrom L; Margolin K; Mortimer JE; Yuan Y; Waisman JR; Lee PP
JCI Insight; 2022 Feb; 7(3):. PubMed ID: 35132960
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
Gao G; Wang Z; Qu X; Zhang Z
BMC Cancer; 2020 Mar; 20(1):179. PubMed ID: 32131780
[TBL] [Abstract][Full Text] [Related]
26. A risk scoring system based on tumor microenvironment cells to predict prognosis and immune activity in triple-negative breast cancer.
Yang A; Wu M; Ni M; Zhang L; Li M; Wei P; Yang Y; Xiao W; An X
Breast Cancer; 2022 May; 29(3):468-477. PubMed ID: 35061208
[TBL] [Abstract][Full Text] [Related]
27. MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer.
Kim YA; Lee HJ; Heo SH; Park HS; Park SY; Bang W; Song IH; Park IA; Gong G
Breast Cancer Res Treat; 2016 Apr; 156(3):597-606. PubMed ID: 27075916
[TBL] [Abstract][Full Text] [Related]
28. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8.
Roychowdhury A; Jondhale M; Saldanha E; Ghosh D; Kumar Panda C; Chandrani P; Mukherjee N
Gene; 2021 Aug; 792():145728. PubMed ID: 34022297
[TBL] [Abstract][Full Text] [Related]
29. Clonality, Antigen Recognition, and Suppression of CD8
Hammerl D; Massink MPG; Smid M; van Deurzen CHM; Meijers-Heijboer HEJ; Waisfisz Q; Debets R; Martens JWM
Clin Cancer Res; 2020 Jan; 26(2):505-517. PubMed ID: 31649042
[TBL] [Abstract][Full Text] [Related]
30. Gene expression patterns associated with tumor-infiltrating CD4+ and CD8+ T cells in invasive breast carcinomas.
Wang Z; Yang X; Shen J; Xu J; Pan M; Liu J; Han S
Hum Immunol; 2021 Apr; 82(4):279-287. PubMed ID: 33612391
[TBL] [Abstract][Full Text] [Related]
31. Tumor infiltrating CD8
Mella M; Kauppila JH; Karihtala P; Lehenkari P; Jukkola-Vuorinen A; Soini Y; Auvinen P; Vaarala MH; Ronkainen H; Kauppila S; Haapasaari KM; Vuopala KS; Selander KS
Oncoimmunology; 2015 Jun; 4(6):e1002726. PubMed ID: 26155410
[TBL] [Abstract][Full Text] [Related]
32. Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling.
Lee HJ; Song IH; Park IA; Heo SH; Kim YA; Ahn JH; Gong G
Oncotarget; 2016 May; 7(21):30119-32. PubMed ID: 27121061
[TBL] [Abstract][Full Text] [Related]
33. Combined evaluation of the FAS cell surface death receptor and CD8+ tumor infiltrating lymphocytes as a prognostic biomarker in breast cancer.
Blok EJ; van den Bulk J; Dekker-Ensink NG; Derr R; Kanters C; Bastiaannet E; Kroep JR; van de Velde CJ; Kuppen PJ
Oncotarget; 2017 Feb; 8(9):15610-15620. PubMed ID: 28121628
[TBL] [Abstract][Full Text] [Related]
34. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
[TBL] [Abstract][Full Text] [Related]
35. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer.
Gao M; Wang T; Ji L; Bai S; Tian L; Song H
Front Immunol; 2020; 11():366. PubMed ID: 32194569
[TBL] [Abstract][Full Text] [Related]
36. Development and validation of a stromal immune phenotype classifier for predicting immune activity and prognosis in triple-negative breast cancer.
Zheng S; Zou Y; Xie X; Liang JY; Yang A; Yu K; Wang J; Tang H; Xie X
Int J Cancer; 2020 Jul; 147(2):542-553. PubMed ID: 32285442
[TBL] [Abstract][Full Text] [Related]
37. Ferritin heavy chain in triple negative breast cancer: a favorable prognostic marker that relates to a cluster of differentiation 8 positive (CD8+) effector T-cell response.
Liu NQ; De Marchi T; Timmermans AM; Beekhof R; Trapman-Jansen AM; Foekens R; Look MP; van Deurzen CH; Span PN; Sweep FC; Brask JB; Timmermans-Wielenga V; Debets R; Martens JW; Foekens JA; Umar A
Mol Cell Proteomics; 2014 Jul; 13(7):1814-27. PubMed ID: 24742827
[TBL] [Abstract][Full Text] [Related]
38. Abundance of Regulatory T Cell (Treg) as a Predictive Biomarker for Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Oshi M; Asaoka M; Tokumaru Y; Angarita FA; Yan L; Matsuyama R; Zsiros E; Ishikawa T; Endo I; Takabe K
Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33086518
[TBL] [Abstract][Full Text] [Related]
39. Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes.
Lee HJ; Lee JJ; Song IH; Park IA; Kang J; Yu JH; Ahn JH; Gong G
Breast Cancer Res Treat; 2015 Jun; 151(3):619-27. PubMed ID: 26006068
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of PD-1 and CD39 in tumor-infiltrating lymphocytes compared with peripheral blood lymphocytes in triple-negative breast cancer.
Zahran AM; Rayan A; Zahran ZAM; Mohamed WMY; Mohamed DO; Abdel-Rahim MH; El-Badawy O
PLoS One; 2022; 17(1):e0262650. PubMed ID: 35051220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]